VANDA PHARMA (VM4.SG)
VANDA PHARMA (VM4.SG) operates in Diversified Metals & Mining.
VANDA PHARMA (VM4.SG) (VM4) - Net Assets
Latest net assets as of September 2024: €541.22 Million EUR
Based on the latest financial reports, VANDA PHARMA (VM4.SG) (VM4) has net assets worth €541.22 Million EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€645.12 Million) and total liabilities (€103.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €541.22 Million |
| % of Total Assets | 83.9% |
| Annual Growth Rate | 22.55% |
| 5-Year Change | 32.6% |
| 10-Year Change | N/A |
| Growth Volatility | 37.11 |
VANDA PHARMA (VM4.SG) - Net Assets Trend (2016–2023)
This chart illustrates how VANDA PHARMA (VM4.SG)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VANDA PHARMA (VM4.SG) (2016–2023)
The table below shows the annual net assets of VANDA PHARMA (VM4.SG) from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €544.91 Million | +3.36% |
| 2022-12-31 | €527.20 Million | +4.41% |
| 2021-12-31 | €504.93 Million | +11.40% |
| 2020-12-31 | €453.27 Million | +10.30% |
| 2019-12-31 | €410.94 Million | +49.21% |
| 2018-12-31 | €275.42 Million | +109.63% |
| 2017-12-31 | €131.39 Million | +0.04% |
| 2016-12-31 | €131.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to VANDA PHARMA (VM4.SG)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 19046700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €700.30 Million | 128.52% |
| Total Equity | €544.91 Million | 100.00% |
VANDA PHARMA (VM4.SG) Competitors by Market Cap
The table below lists competitors of VANDA PHARMA (VM4.SG) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boostheat
PA:ALBOO
|
$81.90K |
|
179720
KO:179720
|
$81.92K |
|
CITIZEN HOLDINGS (CTZ.SG)
STU:CTZ
|
$81.96K |
|
Citrine Global Corp
PINK:CTGL
|
$81.97K |
|
Able C&C Inc.
KQ:078520
|
$81.81K |
|
THE WESTERN UNION - Dusseldorf Stock Exchang
DU:W3U
|
$81.69K |
|
Angel Gold Corp
PINK:ANGCF
|
$81.67K |
|
WEIBO SP ADS-A
MU:2WBA
|
$81.66K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VANDA PHARMA (VM4.SG)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 527,198,000 to 544,910,000, a change of 17,712,000 (3.4%).
- Net income of 2,509,000 contributed positively to equity growth.
- Other factors increased equity by 15,203,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.51 Million | +0.46% |
| Other Changes | €15.20 Million | +2.79% |
| Total Change | €- | 3.36% |
Book Value vs Market Value Analysis
This analysis compares VANDA PHARMA (VM4.SG)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.75x to 0.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.92 | €8.05 | x |
| 2018-12-31 | €5.25 | €8.05 | x |
| 2019-12-31 | €7.67 | €8.05 | x |
| 2020-12-31 | €8.26 | €8.05 | x |
| 2021-12-31 | €9.03 | €8.05 | x |
| 2022-12-31 | €9.28 | €8.05 | x |
| 2023-12-31 | €9.47 | €8.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VANDA PHARMA (VM4.SG) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.30%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.19x
- Recent ROE (0.46%) is below the historical average (3.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -13.71% | -12.33% | 0.69x | 1.60x | €-31.14 Million |
| 2017 | -11.85% | -9.43% | 0.80x | 1.56x | €-28.71 Million |
| 2018 | 9.15% | 13.05% | 0.58x | 1.21x | €-2.33 Million |
| 2019 | 28.12% | 50.86% | 0.47x | 1.18x | €74.46 Million |
| 2020 | 5.15% | 9.40% | 0.47x | 1.18x | €-21.99 Million |
| 2021 | 6.57% | 12.34% | 0.45x | 1.18x | €-17.34 Million |
| 2022 | 1.19% | 2.47% | 0.40x | 1.20x | €-46.44 Million |
| 2023 | 0.46% | 1.30% | 0.30x | 1.19x | €-51.98 Million |
Industry Comparison
This section compares VANDA PHARMA (VM4.SG)'s net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VANDA PHARMA (VM4.SG) (VM4) | €541.22 Million | -13.71% | 0.19x | $81.90K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |